Estimating the burden of vaccine preventable lower respiratory tract disease in primary care, UK: protocol for a prospective surveillance study (AvonCAP GP2).

Primary health care lower respiratory tract infection respiratory syncytial viruses

Journal

BJGP open
ISSN: 2398-3795
Titre abrégé: BJGP Open
Pays: England
ID NLM: 101713531

Informations de publication

Date de publication:
09 Sep 2024
Historique:
received: 31 05 2024
accepted: 27 06 2024
medline: 10 9 2024
pubmed: 10 9 2024
entrez: 9 9 2024
Statut: aheadofprint

Résumé

The true burden of acute lower respiratory tract diseases (aLRTD; includes acute lower respiratory tract infection, acute exacerbation of pre-existing heart failure and chronic lung disease) among adults presenting to primary care, and the proportion that are potentially vaccine preventable, is unknown. To describe aLRTD incidence in adults presenting to primary care; estimate proportions caused by RSV, SARS-CoV-2 and pneumococcus; and investigate disease burden from patient and NHS perspectives. Primary care prospective cohort study conducted in six representative General Practices (total ̴83 000 registered adults) in Bristol, UK. Adults (aged≥18 years) registered at participating General Practices and presenting to primary care (in-hours or out-of-hours) or emergency department (if not admitted) with aLRTD will be eligible and identified by real-time primary care record searches. Researchers will screen electronic GP records, including free text, contact patients to assess eligibility, and offer enrolment in a surveillance study and an enhanced diagnostic study (urine, saliva and respiratory samples; physical examination; and symptom diaries). Data will be collected for all aLRTD episodes, with patients assigned to one of three arms: surveillance, embedded diagnostic, and descriptive dataset. Outcome measures will include clinical and pathogen defined aLRTD incidence rates, symptom severity and duration, NHS contacts and costs, health-related quality of life changes, and mortality (≤30 days post identification). This comprehensive surveillance study of adults presenting to primary care with aLRTD, with embedded detailed data and sample collection, will provide an accurate assessment of aLRTD burden due to vaccine preventable infections.

Sections du résumé

BACKGROUND BACKGROUND
The true burden of acute lower respiratory tract diseases (aLRTD; includes acute lower respiratory tract infection, acute exacerbation of pre-existing heart failure and chronic lung disease) among adults presenting to primary care, and the proportion that are potentially vaccine preventable, is unknown.
AIMS OBJECTIVE
To describe aLRTD incidence in adults presenting to primary care; estimate proportions caused by RSV, SARS-CoV-2 and pneumococcus; and investigate disease burden from patient and NHS perspectives.
DESIGN & SETTING METHODS
Primary care prospective cohort study conducted in six representative General Practices (total ̴83 000 registered adults) in Bristol, UK.
METHOD METHODS
Adults (aged≥18 years) registered at participating General Practices and presenting to primary care (in-hours or out-of-hours) or emergency department (if not admitted) with aLRTD will be eligible and identified by real-time primary care record searches. Researchers will screen electronic GP records, including free text, contact patients to assess eligibility, and offer enrolment in a surveillance study and an enhanced diagnostic study (urine, saliva and respiratory samples; physical examination; and symptom diaries). Data will be collected for all aLRTD episodes, with patients assigned to one of three arms: surveillance, embedded diagnostic, and descriptive dataset. Outcome measures will include clinical and pathogen defined aLRTD incidence rates, symptom severity and duration, NHS contacts and costs, health-related quality of life changes, and mortality (≤30 days post identification).
CONCLUSION CONCLUSIONS
This comprehensive surveillance study of adults presenting to primary care with aLRTD, with embedded detailed data and sample collection, will provide an accurate assessment of aLRTD burden due to vaccine preventable infections.

Identifiants

pubmed: 39251234
pii: BJGPO.2024.0129
doi: 10.3399/BJGPO.2024.0129
pii:
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

Copyright © 2024, The Authors.

Auteurs

Polly Duncan (P)

Centre for Academic Primary Care, University of Bristol, Bristol, United Kingdom polly.duncan@bristol.ac.uk.
Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Ruth Mears (R)

Centre for Academic Primary Care, University of Bristol, Bristol, United Kingdom.
Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Elizabeth Begier (E)

Global Respiratory Vaccines, Medical & Scientific Affairs, Pfizer Inc, Collegeville, United States.

Sanaz Rouhbakhsh Halvaei (SR)

Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Jo Southern (J)

Evidence Generation, Pfizer Inc, Collegeville, United States.

Siân Bodfel Porter (SB)

Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Robin Hubler (R)

Evidence Generation, Pfizer Inc, Collegeville, United States.

Glenda Oben (G)

Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

George Qian (G)

Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Maria Lahuerta (M)

Global Respiratory Vaccines, Medical & Scientific Affairs, Pfizer Inc, Collegeville, United States.

Tim Davis (T)

Centre for Academic Primary Care, University of Bristol, Bristol, United Kingdom.

James Campling (J)

Vaccines Medical Affairs, Pfizer Ltd, Tadworth, United Kingdom.

Hannah Christensen (H)

Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Jennifer Oliver (J)

Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Begonia Morales-Aza (B)

Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Kaijie Pan (K)

EvGen Statistics, Pfizer Research and Development, Pfizer Inc, Collegeville, United States.

Sharon Gray (S)

Evidence Generation, Pfizer Inc, Collegeville, United States.

Catherine Hyams (C)

Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Leon Danon (L)

School of Engineering Mathematics and Technology, University of Bristol, Bristol, United Kingdom.

Bradford D Gessner (BD)

Global Respiratory Vaccines, Medical & Scientific Affairs, Pfizer Inc, Collegeville, United States.
West of England NIHR Clinical Research Network, Bristol, United Kingdom.

Adam Finn (A)

Bristol Vaccine Centre, Schools of Population Health Science and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Alastair D Hay (AD)

Centre for Academic Primary Care, University of Bristol, Bristol, United Kingdom.

Classifications MeSH